{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"86.8","upperLimit":"99.5","value":"96.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"description":"ORR by IRF assessment following the completion of study treatment was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) by IRF assessment using the International Working Group (IWG) Revised Response criteria following the completion of study treatment. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received brentuximab vedotin 1.8 mg/kg, IV infusion, within 1 hour of completing treatment with other IV agents, i.e., cyclophosphamide 750 mg/m\\^2 and doxorubicin 50 mg/m\\^2, on Day 1 of each 21-day cycle, and prednisone tablets, 100 mg daily, orally, on Days 1 through 5, for up to 8 cycles (6 months) or until PD, unacceptable toxicity, whichever occurred first.","id":"OG000","title":"Brentuximab Vedotin + CHP"}],"paramType":"NUMBER","populationDescription":"The FAS consisted of all enrolled participants.","reportingStatus":"POSTED","timeFrame":"Up to approximately 7 months","title":"Overall Response Rate (ORR) by Independent Review Facility (IRF) Assessment Per Revised Response Criteria for Malignant Lymphoma","type":"PRIMARY","unitOfMeasure":"percentage of participants"}